Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2014-02-18 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation - Quarterly Investor Briefing 30 pages 915.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Investor Briefing' and dated 20 February 2014. It contains detailed business updates, sales data by region and product, pipeline and development status, financial overview including unaudited income statements for the quarter ended 31-Dec-13, and year-to-date figures. The content includes forward-looking statements, operational progress, sales performance, and financial data for a quarter, which is consistent with a comprehensive quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or presentation. There is no indication that this is an earnings release (which would be shorter and more summary), nor is it a full annual report. The presence of unaudited financial statements and detailed quarterly operational updates aligns with an Interim / Quarterly Report (IR). Q4 2013
2014-02-18 English
Pharmaxis Quarterly Investor Conference Call 1 page
Call Transcript Classification · 90% confidence The document is a media release announcing a quarterly investor conference call scheduled for 20th February 2014. It mentions that an investor presentation will be lodged prior to the call and provides telephone and online access details for the call. There is no actual transcript of the call or detailed financial data included in this document. The document is short (1149 characters) and serves as an announcement rather than the full transcript or report. Therefore, it fits the category of a Call Transcript announcement or invitation, but since it is not the transcript itself, it is best classified as a Call Transcript (CT) type, as the content is focused on the conference call event. Confidence is high due to clear keywords like 'quarterly investor conference call' and 'recording of the conference will be available'.
2014-02-16 English
Appendix 3B - Exercise of employee options 11 pages 90.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities, terms, and dates relevant to the issuance and quotation on the ASX. The document is a formal announcement of a new issue of shares and application for quotation of additional securities, consistent with regulatory filings for capital changes. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The document is lengthy (over 14,000 characters) and contains detailed information about the securities issued, but it is not an annual or interim report, earnings release, or management discussion. It fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and related capital structure changes.
2014-02-13 English
Appendix 4C - quarterly 6 pages 134.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C: Quarterly Report' and is addressed to ASX Limited, indicating it is a regulatory quarterly report for an entity admitted on the basis of commitments. It contains detailed financial data including consolidated cash flow statements, cash reconciliation, payments to directors, financing facilities, and compliance statements. The report covers the quarter ended 31 December 2013 and includes substantive financial data and analysis for that period. The length of the document (8444 characters) and the detailed financial content confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2014
2014-01-29 English
Appendix 3B - Exercise of employee options 11 pages 90.4KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including specific numbers of shares and options, exercise prices, and expiry dates. The document references ASX rules and is structured as a formal announcement to the Australian Securities Exchange regarding securities issuance and quotation. This matches the description of a Share Issue/Capital Change announcement rather than a full financial report or other filing types. The document length is substantial but the content is focused on securities issuance details, consistent with the 'Share Issue/Capital Change' category.
2013-12-11 English
Scottish Medicines Consortium Accepts Bronchitol for CF Use 2 pages 115.6KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 10th December 2013 announcing that the Scottish Medicines Consortium (SMC) has accepted the pharmaceutical product Bronchitol for use in cystic fibrosis patients in Scotland. It discusses the clinical acceptance and regulatory recommendation of the drug, including references to prior NICE guidance. The content is promotional and informative about a regulatory decision and product acceptance, not a financial report, earnings release, or any form of regulatory filing related to financial performance or corporate governance. It does not contain financial statements, management discussion, or shareholder voting results. It is a public announcement of a regulatory acceptance decision related to a pharmaceutical product. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-12-09 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.